Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.
Location: United States
Total raised: $217M
Investors 2
| Date | Name | Website |
| 16.09.2024 | Vida Ventu... | vidaventur... |
| 01.07.2025 | Omega Fund... | omegafunds... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 04.02.2026 | Series A | $52M | a16z |
| 26.07.2024 | Series A | $165M | - |
Mentions in press and media 11
| Date | Title | Description |
| 04.02.2026 | Third Arc Bio Raises $52M in Series A Extension Funding | Third Arc Bio, a Spring House, PA-based clinical stage biotechnology company, raised $52M in Series A funding. The round was led by Andreessen Horowitz (a16z), with participation from existing investors. As part of the financing, a16z Gener... |
| 04.02.2026 | SynthBee Raises $100M in Funding | SynthBee, a Fort Lauderdale, FL-based collaborative intelligence (CI) platform, raised $100M in funding. The round was led by Crosspoint Capital Partners. The company intends to use the funds to expand operations and its development efforts... |
| 26.07.2024 | The Week’s 10 Biggest Funding Rounds: Space Tech Startup Astranis Tops List | 5 Shares Email Facebook Twitter LinkedIn Want to keep track of the largest startup funding deals in 2024 with our curated list of $100 million-plus venture deals to U.S.-based companies? Check out The Crunchbase Megadeals Board. This is a w... |
| 26.07.2024 | Third Arc Bio Raises $165 Million To Develop Multifunctional Antibodies Optimized For T Cell Engagement | Third Arc Bio – a biotech company developing multifunctional antibodies that are optimized for best-in-class T cell engagement across solid tumors and inflammatory & immunology (I&I) disease – announced a $165 million oversubscribed... |
| 25.07.2024 | Canadian Startups Surge: Clio and Third Arc Bio Lead the Charge** ** | ** In the world of startups, the spotlight often shines brightest on Silicon Valley. Yet, this week, Canadian startups have taken center stage, proving that innovation knows no borders. Two companies, Clio and Third Arc Bio, have made headl... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | -- Company formed and originally seeded by Omega Funds, Series A financing with exceptional syndicate led by Vida Ventures -- World-class leadership team led by Peter F. Lebowitz, MD, PhD, Sanjaya Singh, PhD, and Joe Erhardt, PhD, well-posi... |
| 23.07.2024 | Third Arc Bio Launches with $165M Series A Financing | Third Arc Bio, a Boston, MA-based biotech company developing multifunctional antibodies, raised $165M in Series A funding. The round was led by Vida Ventures and Cormorant Asset Management and Hillhouse Investment. Omega Funds continued als... |
| 23.07.2024 | Third Arc Bio Launches with Oversubscribed $165 Million Series A Financing to Deliver Superior Biologics for Solid Tumors and Inflammatory & Immunology (I&I) Diseases | - |
| 23.07.2024 | Third Arc Bio launches with $165M to address unmet needs in oncology and autoimmunity | The company was founded by executives from Johnson & Johnson Third Arc Bio is a company that says its on mission to deliver transformational therapies for solid tumors and inflammatory & immunology diseases through the use of multif... |
| - | Third Arc Bio | “Third Arc Bio is advancing antibody technology by unlocking the powerful biology of immune synapses to address solid tumors and autoimmune diseases.” |
Show more